Lv71
5000 积分 2021-08-23 加入
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
13天前
已完结
Increased stromal densities of B cells, CD103+ cells, and CD163+ M2-like macrophages associate with poor clinical outcomes in BCG treated non-muscle invasive bladder cancer
4个月前
已完结
European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update
4个月前
已完结
Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Guérin therapy
4个月前
已完结
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
5个月前
已完结
Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
5个月前
已完结
A genetic basis for sex differences in Xp11 translocation renal cell carcinoma
6个月前
已完结
Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations
6个月前
已完结
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
7个月前
已完结
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
7个月前
已完结
皖公网安备34019202002308
